Clinical Trial Update: Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin [Phase 2]

View source ↗

Summary

Phase 2 study evaluating whether TOP2A (topoisomerase II alpha) gene amplification and protein overexpression predict response to epirubicin in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Epirubicin (epirubicin)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED